Navigation Links
Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
Date:9/3/2009

SUNNYVALE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Dr. Glenn Rice, President and COO, will provide a business overview at the following conferences:

-- Thomas Weisel Partners 2009 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 9th at 3:50 p.m. EDT.

-- Rodman & Renshaw 11th Annual Healthcare Conference at the Palace Hotel in New York on Thursday, September 10th at 12:05 p.m. EDT.

There will be a live webcast of the presentations, which will be accessible through a link posted on the investor relations / events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm. The webcasts will be available for replay through October 10th, 2009.

About Pharmacyclics

Pharmacyclics((R)) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us athttp://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmacyclics, Inc. Rights Offering Oversubscribed
2. Pharmacyclics Announces Subscription Price for Rights Offering
3. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
4. Pharmacyclics Files Registration Statement for Rights Offering
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
7. Pharmacyclics Secures $5.0 Million in Debt Financing
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
10. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
11. Pharmacyclics Announces It Received Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
Breaking Biology News(10 mins):